HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
cyqualon
Also Known As:
2,6-bis((3-methoxy-4-hydroxyphenyl)methylene)cyclohexanone; 2,6-divanillylcyclohexanone; 2,6-divanillylidenecyclohexanone; BMHPC; 2,6-bis((4-hydroxy-3-methoxyphenyl)methylene)cyclohexanone
Networked:
4
relevant articles (
0
outcomes,
2
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Ketones: 2618
Cyclohexanones: 5
cyqualon: 4
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Alicyclic Hydrocarbons: 1
Cycloparaffins: 6
Cyclohexanes: 3
Cyclohexanones: 5
cyqualon: 4
Experts
1.
Markaverich, Barry M
: 1 article (12/2012)
2.
Vijjeswarapu, Mary
: 1 article (12/2012)
Related Diseases
1.
Breast Neoplasms (Breast Cancer)
03/01/1993 - "
The results of these studies demonstrated that low doses of BMHPC (2 mug/mL) and FU (0.2 mug/mL) failed to significantly affect MCF-7 human breast cancer cell proliferation.
"
05/01/1992 - "
These findings demonstrate that esterase-stable type II antagonists such as BDHPC and BMHPC inhibit mammary cancer cell proliferation in vitro and in vivo and support earlier studies demonstrating that MeHPLA and functionally related compounds may regulate malignant cell proliferation at the level of this binding site.
"
2.
Neoplasms (Cancer)
05/01/1998 - "
Oral administration of BMHPC to nude mice bearing subcutaneous PC-3 cell xenografts impeded the growth of these solid tumors in vivo without significant signs of toxicity.
"
03/01/1993 - "
However, combination therapy with BMHPC plus FU antagonized tumor growth and no significant treatment effects were observed on fluid consumption or the body weights of these animals.
"
03/01/1993 - "
Similarly, when orally administered to mice at a dose level of 50 mug/mL drinking water, neither BMHPC or FU alone substantially inhibited the growth of estrogen-independent transplantable mammary tumors.
"
05/01/1992 - "
Dose-dependent occupancy of type II sites in MCF-7 human cells by BDHPC and BMHPC directly correlated with the inhibition of cell proliferation, and administration of BDHPC by silastic implant inhibited mouse mammary tumor growth in vivo.
"
3.
Prostatic Neoplasms (Prostate Cancer)
12/01/2012 - "
Treatment of PC-3 human prostate cancer cells with luteolin or BMHPC modulated the expression of a number of genes in the epidermal growth factor receptor signaling pathway (EGFRSP) and cell cycle pathway (CCP).
"
05/01/1998 - "
BMHPC also competed for [3H]estradiol binding to type II sites in LNCaP and PC-3 human prostatic cancer cell lines and this ligand inhibited the proliferation of these cells in a dose and time dependent fashion.
"
4.
Body Weight (Weight, Body)
05/01/1998 - "
No significant treatment effects of BMHPC on seminal vesicular, testicular or body weights were observed.
"
05/01/1998 - "
Oral administration of BMHPC (9.5-38.0 mg/kg body weight per day) to intact adult male Balb/c mice for 14 days resulted in a dose dependent reduction (P<0.01) in prostatic weight relative to controls.
"
03/01/1993 - "
However, combination therapy with BMHPC plus FU antagonized tumor growth and no significant treatment effects were observed on fluid consumption or the body weights of these animals.
"
Related Drugs and Biologics
1.
Esterases
2.
2,6- bis((3,4- dihydroxyphenyl)methylene)cyclohexanone
3.
methyl 4-hydroxyphenyllactate
4.
ErbB Receptors (EGF Receptor)
5.
Drinking Water
6.
Luteolin
7.
Ligands
8.
Estrogens (Estrogen)
9.
Estradiol (Delestrogen)
10.
baysilon (polydimethylsiloxane)
Related Therapies and Procedures
1.
Therapeutics
2.
Oral Administration